LONDON (Alliance News) - Tissue Regenix Group PLC said Monday that it had won a patent to cover the use of its dCELL technology for mensical implants in China.
Mensical implants are used to replace the menisci, the cartilage that acts as a shock absorber in the knee joint.
The company said that the patent was part of its plans to expand in the soft tissue repair and sports medicine sector in China.
Shares in Tissue Regenix were trading up 1.6% at 28.95 pence Monday morning.
By Hana Stewart-Smith; hanassmith@alliancenews.com; @HanaSSAllNews
Copyright 2014 Alliance News Limited. All Rights Reserved.